Search the Newsreel

Taysha Gene Therapies Inc (TSHA) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Taysha Gene Therapies Inc (TSHA), detailing its current valuation score of 8.53, ranking 113 out of 384 in the Biotechnology & Medical Research industry. It highlights the company's current P/E ratio of -15.60, noting its position relative …

BioRestorative Therapies (BRTX) reports director Esha Randhawa’s insider status

BioRestorative Therapies, Inc. (BRTX) has filed an initial statement of beneficial ownership for its director, Esha Randhawa, indicating her insider status. The report, a Form 3, shows no reported transactions, share purchases, sales, or derivative positions for Randhawa. This signifies an initial disclosure of …

BioRestorative Therapies Inc (BRTX) Valuation: PE, PB & Fair Value Analysis

BioRestorative Therapies Inc (BRTX) currently holds a valuation score of 7.70, placing it 153rd out of 385 companies in the Biotechnology & Medical Research industry. The company's P/E ratio is -0.19, which is significantly below its recent high and above its recent low. However, …

Time To Take A Look At Taysha: Rett Syndrome Gene Therapy Trial On Track For Key Interim Analysis

Taysha Gene Therapies is advancing its gene therapy trial for Rett syndrome, a rare neurodevelopmental disorder caused by MECP2 gene mutations, towards a key interim analysis. The article highlights that Rett syndrome primarily affects females, with 6,000-9,000 patients in the US, and notes that …

Happiest Minds Technologies Limited (NSE:HAPPSTMNDS) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

BioRestorative Therapies, Inc. Revenue Breakdown – DUS:9OF

This article provides a revenue breakdown for BioRestorative Therapies, Inc. (DUS:9OF). In the last year, the company generated 306.51K EUR, primarily from its Therapeutic Products and Medical Therapies segment (306.26K EUR), with the majority of revenue originating from the United States.

BioRestorative Therapies Inc

This article for BioRestorative Therapies Inc (BRTX) from TradingKey primarily focuses on the company's revenue breakdown. It indicates that relevant data regarding business segments, regional revenue, and profit contribution have not yet been disclosed by the company. The page also provides basic stock information, …

Happiest Minds Q1 Results: Profit rises 18% YoY to Rs 68 crore; revenue up 14%

Happiest Minds Technologies Limited Provides Earnings Guidance for the Fiscal Year 2027

Stocks to watch, July 28: Coforge, Happiest Minds, HUL, Coal India, HDFC Bank, IndiGo, Tata Power, L&T

Happiest Minds Technologies Limited Reports Earnings Results for the First Quarter Ended June 30, 2026

BioRestorative Therapies Inc (BRTX) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of BioRestorative Therapies Inc (BRTX) regarding its dividend and stock split history. It notes that the company has distributed $0.00 in dividends over the past five years. The page displays current stock information including its market capitalization but shows …

BRTX|BioRestorative Therapies Inc|Price:0.290|Chg%:-0.022

BioRestorative Therapies Inc. (BRTX) is a company focused on developing therapeutic products using adult stem cells, with key programs targeting disc/spine disease and metabolic disorders. Its lead candidate, BRTX-100, is in a Phase II clinical trial for chronic lower back pain. The company also …

Taysha Gene Therapies, Inc. Revenue Breakdown – NASDAQ:TSHA

This article details Taysha Gene Therapies, Inc.'s revenue breakdown for the last year. The company generated $9.77 million USD, with its Gene Therapy segment being the top performer. All reported revenue originated from the United States.

Taysha Gene Therapies Inc (TSHA) Cash Flow

This article provides Taysha Gene Therapies Inc's (TSHA) cash flow statements, including operating, investing, and financing activities, across numerous quarters from FY2020Q3 to FY2026Q1. It details line items such as net income, non-cash items, and changes in working capital. The piece also includes a …

Happiest Minds Shares Advance 1.86% as Company Sets Tomorrow as Ex-Date for Dividend Post-AGM

TSHA|Taysha Gene Therapies Inc|Price:5.520|Chg%:-0.310

Taysha Gene Therapies Inc. (TSHA) currently has a TradingKey Stock Score of 7.22/10, indicating healthy fundamentals and high growth potential, despite a recent weak stock market performance. The company, focused on AAV-based gene therapies for severe monogenic CNS diseases, is considered fairly valued and …

BioRestorative Therapies, Inc. Revenue Breakdown – GETTEX:9OF

This article details the revenue breakdown for BioRestorative Therapies, Inc. (Gettx:9OF), highlighting that in the last year, the company generated 306.51K EUR, primarily from its Therapeutic Products and Medical Therapies segment. The United States was the greatest contributor to this revenue.

Taysha Gene Therapies, Inc. (TSHA) Stock Analysis: Uncovering a Potential 125% Upside in the Biotech Sector

Taysha Gene Therapies (TSHA) is a Dallas-based biotech company specializing in AAV-based gene therapies for severe central nervous system diseases. Analysts project a potential upside of 125.62%, with an average target price of $13.15, despite the company's current operating losses and negative free cash …

Taysha Gene Therapies posts corporate deck highlighting TSHA-102 gene therapy program for Rett syndrome

Taysha Gene Therapies has released a corporate deck providing updates on its TSHA-102 gene therapy program for Rett syndrome. The company anticipates a registration strategy for TSHA-102, a one-time intrathecal AAV9 gene therapy. The REVEAL pivotal trial showed a 100% response rate in Part …

BioRestorative Therapies (BRTX) Q1 2026 Earnings: Narrower Loss Beats Estimates as Company Advances Pipeline - Annual Financial Report

Leadership shake-up at Biorestorative Therapies (NASDAQ: BRTX) and new CEO

BioRestorative Therapies (BRTX) has undergone a significant leadership change, with President, CEO, and Chairman Lance Alstodt and CFO Robert Kristal resigning, claiming "Good Reason" due to an alleged Change in Control and seeking approximately $2.85 million in severance, which the board disputes. Director Katharyn …

BioRestorative Therapies, Inc. Announces CFO Changes, Effective July 13, 2026

BioRestorative Therapies, Inc. announced the resignation of CFO Robert Kristal, effective July 13, 2026, citing "Good Reason" due to a Change in Control related to Board changes in June 2026. The Board disputes the validity of the claims and has initiated an investigation into …

Does Rett Trial Data and Share Offering Reshape the Bull Case for Taysha Gene Therapies (TSHA)?

Happiest Minds Technologies Ltd. Actuals & Estimates (NSE:HAPPSTMNDS)

HAPPSTMNDS Forecast — Price Target — Prediction for 2027

BRTX Q1 2026 Earnings: EPS Beat Drives Stock Higher Despite No Revenue - EBITDA Estimate Trend

BRTX Q1 2026 Earnings: Narrowed Loss Per Share Beats Estimates, Stock Rises - Dividend Growth Analysis

BRTX Q1 2026 Earnings: EPS Surprises with Wider-Than-Expected Beat as Pipeline Advances - One-Time Loss Impact

BioRestorative Therapies Inc. (BRTX) Q1 2026 Earnings: Narrowing Losses Drive Strong Stock Surge - Book Value Growth

Happiest Minds FY26 PAT rises 15.1% to ₹21,263 lakh

Happiest Minds, HG Infra, Cummins India, Greenpanel: Share price targets

Happiest Minds fixes July 17 as record date for final dividend

Happiest Minds Q4 result: Net profit jumps 80% to ₹61 crore; revenue up 11%

Happiest Minds Technologies Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026

Q4 Results Today: Ashok Leyland, Happiest Minds, Graphite India, ITI Among 475+ Firms To Report Earnings